



Investor Presentation

Full Year 2026 Results

August 2026

**Treatment focused.
Technology driven.**

Disclaimer

This document has been prepared as a summary only and does not contain all information about SomnoMed Limited's (the Company's) assets and liabilities, financial position and performance, profit and losses and the rights and liabilities attaching to the Company's securities. This document should be read in conjunction with any public announcements and reports (including financial reports and disclosure documents) released by the Company. The securities issued by the Company are considered speculative and there is no guarantee that they will make a return on the capital invested, that dividends will be paid on the Shares or that there will be an increase in the value of the Shares in the future.

Some of the statements contained in this release are forward-looking statements. Forward looking statements include but are not limited to, statements concerning estimates of future sales, expected revenues and costs, statements relating to the continued advancement of the Company's operations and other statements which are not historical facts. When used in this document, and on other published information of the Company, the words such as "aim", "could", "estimate", "expect", "intend", "target", "forecast", "future", "will", "may", "potential", "should" and similar expressions are forward-looking statements.

Although the company believes that its expectations reflected in the forward-looking statements are reasonable, such statements involve risk and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Various factors could cause actual results and projections of future performance to differ from these forward-looking statements as a result of known and unknown risks, uncertainties and other factors not anticipated by the Company or disclosed in the Company's published material. Many of these factors are beyond the control of the Company Limited and may involve subjective judgement and assumptions as to future events, which may or may not be correct.

The Company does not purport to give financial or investment advice. No account has been taken of the objectives, financial situation or needs of any recipient of this document.

Recipients of this document should carefully consider whether the securities issued by the Company are an appropriate investment for them in light of their personal circumstances, including their financial and taxation position.

Company Highlights



SomnoMed is the global market leader in oral appliance therapy

With over 1 million patients treated worldwide and leading positions across multiple geographies, SomnoMed is well positioned to capitalise on the market opportunity and drive growth

VISION

A world where our oral appliance therapy is the standard of care for obstructive sleep apnea treatment (OSA).

MISSION

As the global leader in oral appliance therapy (OAT), we set the standard for outcomes, innovation and patient experience – driving the transformation of sleep medicine worldwide.

LARGE AND GROWING MARKET



Significant total addressable patient market with ~1 Billion individuals suffering from OSA globally.



Total potential customer market of 700K+ dentists in key regions



Increasing OSA consumer awareness, growth in GLP-1 drugs, and demand for CPAP alternatives is growing the OAT market.



SomnoMed is the global market leader in oral appliances for OSA and well positioned to drive growth.

Financial Highlights

Strong foundation established to deliver on strategic initiatives

Solid Financial Results (FY26)

- **EBITDA¹** - Up 19% to \$10.9m, 9.6% margin
- **Revenue** - Up 3% to \$114.5m, led by North America (NAM)

Disciplined Cost / Capital Management

- **FY26 cost discipline** contributing to double digit EBITDA growth
- **Over 50% of Capex** spend driven by growth initiatives and manufacturing capacity investment

Robust Balance Sheet

- **Positive operating cash flow** before and after leases of +\$8.3m and +\$5.2m
- **Cash position** maintained at \$17.2m (net cash \$16.8m)

¹ EBITDA excludes leases payments (\$3.1m), share/option expenses (\$3.6m), unrealised foreign exchange gain/(loss) (\$1.1m), one-off costs (\$0.7m - tranche 3 restructure) and discontinued operations (nil).

Operational Highlights

Strong foundation established to deliver on strategic initiatives

Experienced Leadership

Executive management update for FY26 and FY27 to date:

- **Karen Borg** – sole CEO
- **Greg Knight** – COO
- **Nathan Minnich** – CMO

With thanks to Amrita Blickstead – stepped down as Co-CEO 27 July 2026

Production Improvements


- **Manufacturing capacity** expanded by over 20% in FY26 and over 40% across 2 years
- **Manufacturing production** times improved by over 50% across 2 years

Product Innovation (Virtus)

- **~50%¹** of OSA patients have co-existing sleep bruxism
- **Virtus** designed to target patients with OSA and sleep bruxism
- **Controlled market release** underway globally


¹ Li D, Kuang B, Lobbezoo F, de Vries N, Hilgevoord A, Aarab G. A large scale polysomnographic study involving 914 adults with OSA published in March 2023 found that sleep bruxism is highly prevalent in adults with obstructive sleep apnea. Journal of Clinical Sleep Medicine. 2023;19(3):443-451.

FY2026 Results




Financial Highlights

Revenue growth




- 1H FY revenue (up 13% and 8% constant currency (CC)²) driven by North America and Europe performance.
- 2H FY26 revenue (down 7% and 1% in CC) impacted by a change in Europe market dynamics and appreciation of the Australian dollar.

EBITDA¹ growth



- EBITDA¹ and margin improvement on higher revenue, improved gross margin and disciplined operating cost management.

Positive operating cash flow after leases




- Increase in operating cash flow after leases, reflective of FY26 revenue growth and disciplined costs management

¹ EBITDA excludes leases payments (\$3.1m), share/option expenses (\$3.6m), unrealised foreign exchange gain/(loss) (\$1.1m), one-off costs (\$0.7m - tranche 3 restructure) and discontinued operations (nil).

² Constant currency calculated using FY25 prior year rates of 0.65 USD/AUD and 0.59 EUR/AUD. Approximately 95% of the Company's revenues are in non-AUD currencies.


Regional Revenue Highlights

Europe




- Our most mature region
- Following a strong 1H, the region faced reimbursement and referral path headwinds that negatively impacted growth in 2H

North America



- Our primary growth region
- Performed strongly, in line with expectations

APAC



- Our first commercial region
- Cost of living pressures impacted patient demand across the non-reimbursed markets

Profit or Loss Summary

\$m	FY26	FY25	%
Revenue	114.5	111.5	+3%
Gross profit	70.0	66.7	+5%
Sales and marketing expenses	(23.0)	(22.9)	+0%
Administrative and other expenses	(19.0)	(18.4)	+3%
Operating profit	28.1	25.4	+10%
Corporate, research and business development expenses	(17.1)	(16.2)	+5%
EBITDA¹	10.9	9.2	+19%
Depreciation and amortisation expenses	(2.8)	(3.1)	-10%
Leases	(3.1)	(3.0)	+4%
Interest	-	(0.1)	-100%
Other ²	(5.5)	(3.8)	+45%
Loss before tax	(0.5)	(0.8)	-40%
Tax	(2.2)	(2.7)	-19%
Net loss after tax	(2.7)	(3.5)	-23%
Key metrics	FY26	FY25	% point
MAS (device) gross margin %	71.5%	70.3%	+1.2
Group gross margin %	61.1%	59.9%	+1.2
EBITDA ¹ margin	9.6%	8.2%	+1.4

Other²

- Increase primarily from higher share-based payment expenses (non-cash).

Tax

- Tax expenses represent operating profits across Europe and North America.

Margins

- Stronger margins across all key metrics despite Europe market dynamics and FX headwinds.

¹ EBITDA excludes leases payments (\$3.1m).

² Other represents share/option expenses (\$3.6m), unrealised foreign exchange gain/(loss) (\$1.1m), one-off costs (\$0.7m - tranche 3 restructure) and discontinued operations (nil).

³ Figures may not sum due to rounding.

Balance Sheet Summary

\$m	30 June 2026	30 June 2025
Cash and cash equivalents	17.2	17.3
Trade and other receivables	14.5	18.5
Inventories	7.4	7.4
Property, plant and equipment	7.6	7.0
Intangible assets	22.4	21.5
Right of use asset	4.7	6.9
Deferred tax assets	1.3	2.4
Total assets	75.0	81.0
Trade and other payables	16.4	19.5
Borrowings	0.4	0.8
Provisions	4.7	5.3
Current tax liabilities	1.0	1.8
Lease liabilities	5.0	7.2
Total liabilities	27.6	34.6
Net assets	47.4	46.4

Working capital

- Improvement in collections.
- Lower prepayments and costs accruals.

Borrowings

- Residual debt represents European government backed borrowings.

¹ Figures may not sum due to rounding.

Cash Flow Summary

\$m	FY26	FY25	
EBITDA¹	10.9	9.2	
Movement in working capital and other non-cash	(0.4)	(0.1)	
Tax paid	(1.4)	(0.8)	
One-off expenses	(0.9)	(0.5)	One-off expenses Related to cash settlement of prior year and current year one-off cost provisions.
Operating cash flow (before leases)	8.3	7.8	
Payment of finance leases ²	(3.1)	(3.0)	
Operating cash flow (after leases)	5.2	4.8	
Payments for intangible assets	(2.5)	(1.6)	Investing Continued investments in manufacturing infrastructure and R&D.
Payments for property, plant and equipment	(3.3)	(2.4)	
Investing cash flow	(5.7)	(4.0)	
Free cash flow	(0.6)	0.8	
Proceeds from repayment of loan by Employee Share Trust	2.0	-	Employee share trust transaction Net \$2.0m of proceeds from repayment of loan in relation to 2.86m shares by SomnoMed's employee share trust.
Repayment of borrowings	(0.3)	(0.3)	
Financing cash flow	1.6	(0.3)	
Net cash flow before exchange rate adjustments	1.1	0.4	
Exchange rate adjustments	(1.2)	0.7	FX Reflects appreciation of AUD against key currencies (primarily USD and EUR) in FY26. Approximately 95% of the Company's revenues are in non-AUD currencies.
Net cash flow	(0.1)	1.1	

¹ EBITDA excludes leases payments (\$3.1m), share/option expenses (\$3.6m), unrealised foreign exchange gain/(loss) (\$1.1m), one-off costs (\$0.7m - tranche 3 restructure) and discontinued operations (nil).

² Lease cost of \$3.1m presented under financing cash flow for statutory accounts.

³ Figures may not sum due to rounding.

Strategy and Outlook



Market Dynamics



CPAP failures: up to 50% of patients discontinue therapy¹



OAT competitors: growth in lower cost products & clinical differentiation challenges



Pharma entrants: GLP-1s / emerging drugs are driving patient growth



Neurostimulation: newer, high-cost, invasive surgical procedures are entering the market



DTC models: emerging but nascent

1. Drigo R, Ballarin A, Menzella F, et al. Nature and Science of Sleep. 2025;17:357-363. doi:10.2147/NSS.S501341

From Turnaround to Sustainable Growth

FY24 - FY26

Financial & Operational Turnaround

- ✓ Financial: cleared debt, generated positive cashflow
- ✓ People and culture: investment in talent
- ✓ Operational: capacity increase to improve turnaround times



FY27 - FY30

Growth & Profitability Objectives

- Return to double digit revenue growth
- Progressively expand EBITDA¹ margins through scale and efficiency gains
- Organic growth-focus; consideration of small-scale acquisition opportunities

¹ EBITDA excludes leases payments, share/option expenses, unrealised foreign exchange gain/(loss), one-off costs and discontinued operations.

Market-Leading Portfolio Tailored by Region

Flex & Fusion®

Established European Platforms
Reimbursed across Key European Markets



Herbst Advance Elite®

Designed for US Reimbursement
Medicare Reimbursed



Virtus

Next-Generation OAT Innovation
Global Controlled Release Underway



Commercial Focus to Drive Growth



North America

- Product innovation targeting most accessible Centre for Medicare and Medicaid Services (CMS) codes
- Strategies implemented to drive demand within specific key customer cohorts



Europe

- Restructured commercial and operational leadership to improve customer experience
- Developed dedicated product strategies to respond to the changing environment
- Application underway to improve reimbursement in key market



APAC

- Continued engagement with GLP-1 manufacturer
- Investigating product line extensions for non-reimbursed environment

A Bold Vision to Drive Growth FY27 & Beyond

Strategic roadmap to be detailed at the upcoming Annual General Meeting.

1. Capture the Growing Patient Pool

- GLP-1s and other pharma-led trends
- Connected Care and home diagnostics
- CPAP failures

2. Accelerate New Products Aligned to Market Needs

Existing: HAE®, Classic, Flex, Fusion®

New: Virtus

Future: Connected Care / Rest Assure®

3. Expand Referring and Treating Clinicians

- Clinician connectivity & engagement
- Expanded reimbursement framework

FY27 – Outlook

Setting the stage for growth

As announced on 27 July 2026, the Company is targeting high single digit revenue growth in FY27 while maintaining EBITDA¹ margins consistent with FY26.


FY27 guidance range is expected to be issued as part of the 2026 Annual General Meeting.

Key assumptions and sensitivities:

- 1. Continued NAM growth and EU stabilisation*
- 2. Successful global adoption of Virtus - H2 FY27*
- 3. Stable EBITDA¹ margins while investing to support future growth*
- 4. FX movements*

¹ EBITDA excludes leases payments, share/option expenses, unrealised foreign exchange gain/(loss), one-off costs and discontinued operations.

Q&A





Thank You

For further information please contact:

Investor Relations: IR@somnomed.com.au